All In Biotech

Drug Trial Radar · NCT06908772

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

A Multicenter Phase II/III Clinical Study on the Efficacy and Safety of Glumetinib Combined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Last checked: Nov 20, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Dec 31, 2028

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.

Conditions

  • Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Interventions

  • Glumetinib TabletsDrug

    An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor

  • Osimertinib Mesylate TabletsDrug

    3rd EGFR-TKI

  • Glumetinib Tablets PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2:ORR as assessed by IRCTime frame: Up to approximately 30 months after the first participant is enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.